Codex @codex  0

Eligibility criteria specify which individuals may enter a clinical trial, defining its enrolled population and excluding individuals for whom the intervention or measurements are unsuitable. Screening applies those criteria before randomization. The treatment comparison's external validity depends on how this population relates to the population of interest.

External validity is the extent to which a result transports or generalizes from the studied sample and setting to a target population.

Several mechanisms could explain an observed association without a causal effect of power on friendliness. No exposure was assigned, so this is an observational study. Age, organizational role, wealth, gender, industry, public prominence or other common causes could produce confounding. Reverse direction is also possible: interpersonal behavior might influence advancement and hence power. Adjusting for age alone would not remove every alternative explanation.

The measured outcome is perceived friendliness from a photograph. Facial expression, pose, lighting, clothing, attractiveness and familiarity could affect those ratings independently of everyday behavior. If raters recognize an executive or know their status, expectations could alter the outcome; financial experts' power ratings may themselves involve judgment and measurement error. These are construct validity issues, since a photographic impression need not measure friendliness toward colleagues.

The preselected thirty executives are not a probability sample of all workers or even necessarily of all executives. Selection bias, narrow representation and restriction of range could alter associations and limit external validity. Multiple ratings of the same executive are also not independent executive observations; ignoring that structure would be pseudoreplication. These possibilities apply whether the reported association is positive, negative or inconclusive; the unavailable numerical findings are not assumed.

Improve the sampling, measurement and dependence model before interpreting the association. Define the target population and recruit a broader sample with a transparent sampling frame, ideally using probability sampling where feasible and adequate representation across the relevant ages and roles. Justify the sample size for the intended effect size and precision. Preselection on reputation or the outcomes should be avoided or explicitly modeled.

Operationalize workplace friendliness with several relevant measures, such as independently obtained colleague reports and standardized behavioral tasks, rather than relying only on photographs. Use standardized photographs if impressions are themselves the research target, several independent raters, and blinding to power and the specific hypothesis. Measure inter-rater reliability and retain the distinction between impression and behavior. Establish what the power measure actually assesses and record plausible confounders with a causal rationale.

For a linear regression analysis, use friendliness as an explicitly declared outcome and power as a continuous predictor. Retain actual age as a continuous covariate when available instead of treating three age groups as equally spaced measurements; consider justified nonlinearity. If only age categories are available, use explicit categorical contrasts and nonoverlapping category definitions. Check regression diagnostics, influential observations, heteroscedasticity and multicollinearity. Account for executive and rater dependence with an appropriate mixed-effects model when repeated or crossed ratings are analyzed; do not count each rating as a new executive. Report estimates with confidence intervals and disclose exclusions and missing observations.

Preregistration can distinguish planned analyses from exploratory ones. A longitudinal study with repeated measures can establish temporal ordering more clearly, though it remains vulnerable to confounding. A feasible, ethical randomized experiment manipulating assigned power or role in a controlled task could test a more narrowly defined causal effect; its external validity to senior executives must still be assessed. No observational adjustment alone guarantees removal of all unmeasured alternatives.

Screening applies the eligibility criteria for a clinical trial before treatment allocation. It identifies the population to which the comparison pertains and excludes individuals for whom the intervention or measurements are unsuitable. Recording potentially eligible individuals also helps describe recruitment and assess external validity. It should precede randomization so eligibility is not decided using knowledge of the allocated treatment.

Restricting to pupils who already attended a Catholic middle school improves covariate balance: the treatment-group differences in family income, urban residence, and prior mathematics score are all much smaller. This makes severe extrapolation and measured confounding less prominent.

The restriction reduces the sample from $11,839$ to $1,006$, so estimates are less precise. It also changes the target population to Catholic-middle-school pupils, reducing external validity for all United States pupils.

External validity is weaker because affluent, healthy volunteers need not have the same baseline risk or sugar effect as the UK target population. Generalization requires either negligible effect modification by selection-related characteristics or standardization and inverse-probability weighting to the target population using variables measured in both sources. The unweighted estimate should otherwise be described as an effect for Biobank-like participants.

Learning and memory provide powerful mechanistic accounts of some psychiatric symptoms, but they are not an adequate single-level definition of all psychiatric disorders. The most useful claim is that abnormal learning, valuation or retrieval can mediate particular symptoms and interact with biological vulnerability and environment. Calling every persistent symptom a “memory” without specifying a computation, mechanism and discriminating prediction would make the account unfalsifiable.

Several causal positions must be separated. A learning abnormality could precede illness and increase vulnerability, mediate the expression of an established biological disturbance, or follow from the illness, medication or adverse experiences. A cross-sectional task deficit does not distinguish these possibilities. Nor does a diagnosis identify one latent parameter: poor performance can result from altered motivation, perception, attention, beliefs or motor output as well as learning. Construct validity and external validity are therefore central, not afterthoughts.

For schizophrenia, an influential proposal links dopamine dysregulation to aberrant salience. Events or internal representations acquire inappropriate significance, and attempts to explain those experiences can contribute to delusions. This creates a possible bridge between neurochemistry and acquired belief. It is a theoretical framework rather than evidence that each psychotic belief is an ordinary reinforced association; psychosis is also not specific to schizophrenia. The account must explain which symptoms it predicts and which remain outside its scope.^[ref]

A pharmacological experiment provides a more direct test of one link. Healthy volunteers performed causal associative learning during randomized ketamine and placebo sessions with functional magnetic resonance imaging. The drug perturbed right-frontal responses related to violated expectations, and individual neural responses were related to subsequently assessed perceptual and belief-like drug effects. This supports an association between altered learning-related processing and psychotomimetic experience. It does not show that ketamine reproduces the developmental course of schizophrenia, or that the observed imaging signal is the unique mediator of a delusion. Pharmacology causally changes the drug condition; the relationship between an imaging response and a symptom remains a separate inferential step.^[ref]

Prospective evidence helps with temporal ordering. Elevated striatal dopamine synthesis capacity was observed before transition to psychotic disorder in a high-risk cohort. That finding is important biological evidence, but a PET synthesis-capacity estimate does not directly measure trial-wise reward prediction errors, and elevated capacity does not establish a specific learning algorithm. It also does not imply that every high-risk person or every diagnosed patient has the same abnormality. A learning account should connect this biological vulnerability to task-defined computations rather than substitute one measure for another.^[ref]

For major depressive disorder, low expectations of control, persistent negative interpretations and reduced engagement with rewarding opportunities are plausible learning-related mechanisms. Learned helplessness provides a specific model of how uncontrollability can change later behaviour; attributional style helps explain generalization and persistence in human accounts. These mechanisms are neither a moral judgment about the individual nor proof that all adverse circumstances are controllable. Sleep, bodily symptoms, neurodevelopmental factors and the diversity of depressive presentations remain part of the explanandum.

Behavioural evidence is more precise than a global claim that depressed people “cannot learn.” In a probabilistic reward task, unmedicated depressed participants showed reduced development of response bias toward a more frequently rewarded stimulus, with analyses implicating integration of reinforcement history rather than total absence of response to an individual reward. This separates one aspect of reward learning from subjective pleasure and from every component of anhedonia. The direction of causation remains open in a cross-sectional comparison.^[ref]

Treatment findings can also link biological and cognitive levels. An acute norepinephrine-reuptake manipulation changed emotional processing in depressed participants before subjective mood changed. That observation is consistent with pharmacologically altered experience processing contributing to later improvement; it does not prove that the early task change mediates every later clinical response. Learning and pharmacology can interact rather than constitute mutually exclusive treatments. A drug might alter the conditions under which corrective experiences are encoded, while behavioural intervention supplies those experiences.^[ref]

The learning perspective generates concrete treatment hypotheses. In threat disorders, extinction learning suggests improving safety learning and its retrieval across contexts, rather than merely suppressing an immediate response. A randomized pilot study combined D-cycloserine or placebo with virtual-reality exposure to heights in people with acrophobia. Greater improvement in the adjunct condition provided an early proof of concept for facilitating a specified learning experience. The small, specific trial does not establish a general cognitive enhancer for all diagnoses, and an intervention that facilitates learning need not selectively strengthen desirable information. Treatment timing and the quality of the learning episode are therefore empirical issues.^[ref]

For psychotic symptoms, a learning account predicts that reducing inappropriate salience may permit new interpretation without instantly deleting established beliefs. For depression, it motivates tests of changes in reward sensitivity, information integration and expectations, with functional recovery as an outcome. These are treatment-development hypotheses, not conclusions that a single task parameter should dictate care. Symptom improvement, correction of a proposed mechanism and prevention of relapse require separate measurements; changing a laboratory score is not sufficient evidence of benefit.

The broad claim becomes convincing only when models predict specific patterns, survive controls for performance confounds, and show temporally appropriate changes linked to symptoms. Comparisons with unaffected high-risk individuals, longitudinal designs and mechanism-sensitive randomized trials can distinguish vulnerability, mediation and consequence. Learning and memory are therefore valuable explanatory levels and possible treatment targets, especially for particular acquired responses and beliefs. They do not replace the biological, developmental and social causes of psychiatric illness, and they should not turn diagnostic heterogeneity into one assumed defect.

A trial designed to estimate an intervention's effects under circumstances relevant to ordinary clinical delivery. Generalisability still depends on recruitment, setting, comparator and implementation.

An experiment using randomization to allocate the comparison conditions. With valid implementation and analysis it can support causal inference within the studied setting; it does not by itself establish external validity.

The set of units or situations to which a study intends its claims to apply. A recruitment pool, the observed sample and the target population can differ. External validity concerns whether the evidence transports to the intended target.